Michelle Mellion
QMedic(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Genetic Neurodegenerative Diseases, Multiple Sclerosis Research Studies, Ubiquitin and proteasome pathways, CAR-T cell therapy research
Most-Cited Works
- → A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis(2013)224 cited
- → Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial(2019)177 cited
- → Alcohol‐related peripheral neuropathy: Nutritional, toxic, or both?(2011)143 cited
- → Safety of nerve conduction studies in patients with implanted cardiac devices(2006)52 cited
- → Small-Fiber Degeneration in Alcohol-Related Peripheral Neuropathy(2014)44 cited
- → Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement(2021)37 cited
- → Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial(2024)31 cited
- → Experimental Alcohol-Related Peripheral Neuropathy: Role of Insulin/IGF Resistance(2012)28 cited
- → Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI(2022)26 cited
- → Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004)(2017)23 cited